CHAPTER 1INTRODUCTION

1.1.REPORT DESCRIPTION
1.2.KEY BENEFITS
1.3.KEY MARKET SEGMENTS
1.4.RESEARCH METHODOLOGY

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models

CHAPTER 2EXECUTIVE SUMMARY

2.1.CXO PERSPECTIVE

CHAPTER 3MARKET OVERVIEW

3.1.MARKET DEFINITION AND SCOPE
3.2.KEY FINDINGS

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.MARKET SHARE ANALYSIS, 2016
3.4.PORTER’S FIVE FORCES ANALYSIS

3.4.1.MARKET DYNAMICS
3.4.2.Drivers
3.4.3.Restraints
3.4.4.Opportunities

CHAPTER 4METAXALONE MARKET, BY INDICATION

4.1.OVERVIEW

4.1.1.Market size and forecast

4.2.BONE PAIN

4.2.1.Key market trends
4.2.2.Growth factors and opportunities
4.2.3.Market size and forecast

4.3.MUSCLE PAIN

4.3.1.Key market trends
4.3.2.Growth factors and opportunities
4.3.3.Market size and forecast

4.4.JOINT PAIN

4.4.1.Key market trends
4.4.2.Growth factors and opportunities
4.4.3.Market size and forecast

4.5.TUNNEL SYNDROMES

4.5.1.Key market trends
4.5.2.Growth factors and opportunities
4.5.3.Market size and forecast

4.6.OTHERS

4.6.1.Key market trends
4.6.2.Growth factors and opportunities
4.6.3.Market size and forecast

CHAPTER 5METAXALONE MARKET, BY GEOGRAPHY

5.1.OVERVIEW
5.2.NORTH AMERICA

5.2.1.Key market trends
5.2.2.Key growth factors and opportunities
5.2.3.Market size and forecast

5.2.3.1.U.S. market size and forecast
5.2.3.2.Canada market size and forecast
5.2.3.3.Mexico market size and forecast

5.2.4.North America Metaxalone Market by Indication

5.3.EUROPE

5.3.1.Key market trends
5.3.2.Key growth factors and opportunities
5.3.3.Market size and forecast

5.3.3.1.Germany market size and forecast
5.3.3.2.France market size and forecast
5.3.3.3.UK market size and forecast
5.3.3.4.Italy market size and forecast
5.3.3.5.Spain market size and forecast
5.3.3.6.Rest of Europe market size and forecast

5.3.4.Europe Metaxalone Market by Indication

5.4.ASIA-PACIFIC

5.4.1.Key market trends
5.4.2.Key growth factors and opportunities
5.4.3.Market size and forecast

5.4.3.1.Japan market size and forecast
5.4.3.2.China market size and forecast
5.4.3.3.Australia market size and forecast
5.4.3.4.India market size and forecast
5.4.3.5.South Korea market size and forecast
5.4.3.6.Taiwan market size and forecast
5.4.3.7.Rest of Asia-Pacific market size and forecast

5.4.4.Asia-Pacific Metaxalone Market by Indication

5.5.LAMEA

5.5.1.Key market trends
5.5.2.Key growth factors and opportunities
5.5.3.Market size and forecast

5.5.3.1.Brazil market size and forecast
5.5.3.2.Turkey market size and forecast
5.5.3.3.Saudi Arabia market size and forecast
5.5.3.4.South Africa market size and forecast
5.5.3.5.Rest of LAMEA market size and forecast

5.5.4.LAMEA Metaxalone Market by Indication

CHAPTER 6COMPANY PROFILES

6.1.BIOSYNTH

6.1.1.Operating business segments
6.1.2.Business performance
6.1.3.Key strategic moves and developments

6.2.CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD.

6.2.1.Operating business segments
6.2.2.Business performance
6.2.3.Key strategic moves and developments

6.3.SIGMA-ALDRICH CO. LLC

6.3.1.Operating business segments
6.3.2.Business performance
6.3.3.Key strategic moves and developments

6.4.CDI TECHNOLOGY

6.4.1.Operating business segments
6.4.2.Business performance
6.4.3.Key strategic moves and developments

6.5.ANGELINI S.P.A.

6.5.1.Operating business segments
6.5.2.Business performance
6.5.3.Key strategic moves and developments

6.6.PFIZER INC.

6.6.1.Operating business segments
6.6.2.Business performance
6.6.3.Key strategic moves and developments

6.7.AURUM PHARMATECH LLC

6.7.1.Operating business segments
6.7.2.Business performance
6.7.3.Key strategic moves and developments

6.8.FINETECH INDUSTRY LIMITED

6.8.1.Operating business segments
6.8.2.Business performance
6.8.3.Key strategic moves and developments

6.9.BIOCORE

6.9.1.Operating business segments
6.9.2.Business performance
6.9.3.Key strategic moves and developments

6.10.OXCHEM CORPORATION

6.10.1.Operating business segments
6.10.2.Business performance
6.10.3.Key strategic moves and developments